Abstract | AIMS AND BACKGROUND: PATIENTS AND METHODS: Thirty-eight consecutive women with metastatic breast cancer (PS < or =2) were entered in this phase II trial; all patients had been previously treated for metastatic disease with chemotherapy containing anthracyclines and had shown a progression of the disease during drug administration or after a clinical response lasting less than 6 months. Fifteen patients had received 2 or more chemotherapeutic regimens for advanced disease; 31 patients had > or =2 sites of metastatic disease. Paclitaxel (135 mg/m2) was administered iv by a 3-hr infusion followed by iv infusion of cisplatin (75 mg/m2) on day 1, every 3 weeks for 6 cycles. After the completion of the planned chemotherapy administration, 9 responsive patients continued to receive paclitaxel alone (175 mg/m2) iv, on day 1, every 3 weeks, until disease progression or unacceptable toxicity. RESULTS: A partial clinical response was recorded in 17 cases (45%; 95% CI, 30-64%). The median duration of overall response was 8 months; for the 9 responsive patients who continued treatment with paclitaxel alone, 4 had maintained the partial clinical response at the median follow-up of 24 months from the onset of therapy. The median time to progression was 6 months and median overall survival 8 months. Neurotoxicity was the most frequent adverse effect and caused treatment discontinuation in 5 cases for grade 3-4 paresthesia and/or an arthralgia/ myalgia syndrome. Grade 3-4 neutropenia occurred in 16 patients (44%). CONCLUSIONS:
|
Authors | G Rosati, F Riccardi, A Tucci, P De Rosa, G Pacilio |
Journal | Tumori
(Tumori)
2000 May-Jun
Vol. 86
Issue 3
Pg. 207-10
ISSN: 0300-8916 [Print] United States |
PMID | 10939600
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Cisplatin
|
Topics |
- Adult
- Aged
- Antibiotics, Antineoplastic
(therapeutic use)
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Breast Neoplasms
(drug therapy, pathology)
- Cisplatin
(administration & dosage)
- Disease Progression
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Female
- Humans
- Male
- Middle Aged
- Paclitaxel
(administration & dosage)
- Peripheral Nervous System Diseases
(chemically induced)
- Survival Analysis
- Treatment Outcome
|